Purple glove syndrome

Results: 10



#Item
1Summary of Safety Information about Purple Glove Syndrome in Association with Intravenous Administration of Phenytoin and Fosphenytoin November 3, 2010  Susan Welsh

Summary of Safety Information about Purple Glove Syndrome in Association with Intravenous Administration of Phenytoin and Fosphenytoin November 3, 2010 Susan Welsh

Add to Reading List

Source URL: www.fda.gov

Language: English
2<Title (Maximum 255 Characters)>

<Title (Maximum 255 Characters)>

Add to Reading List

Source URL: www.fda.gov

Language: English
3U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

Add to Reading List

Source URL: www.fda.gov

Language: English
4U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

Add to Reading List

Source URL: www.fda.gov

Language: English
5Review of Fentora® and Actiq® Adverse Events from the Adverse Event Reporting System (AERS) Database

Review of Fentora® and Actiq® Adverse Events from the Adverse Event Reporting System (AERS) Database

Add to Reading List

Source URL: www.fda.gov

Language: English
6Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of the Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and Drug Safety and Risk Management Advisory

Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of the Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and Drug Safety and Risk Management Advisory

Add to Reading List

Source URL: www.fda.gov

Language: English
7SOPP 8420: FDAAA Section 921: Posting of Potential Signals of Serious Risk Version #1 Effective Date: November 1, 2011  I. Purpose

SOPP 8420: FDAAA Section 921: Posting of Potential Signals of Serious Risk Version #1 Effective Date: November 1, 2011 I. Purpose

Add to Reading List

Source URL: www.fda.gov

Language: English
8U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

Add to Reading List

Source URL: www.fda.gov

Language: English
9FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Peripheral and Central Nervous System Drugs Advisory Committee Meeting Hilton Washington DC/Silver Spring, The Ballrooms 8727 Colesville R

FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Peripheral and Central Nervous System Drugs Advisory Committee Meeting Hilton Washington DC/Silver Spring, The Ballrooms 8727 Colesville R

Add to Reading List

Source URL: www.fda.gov

Language: English
10DPV-1 suggested questions/discussion topics for the AC

DPV-1 suggested questions/discussion topics for the AC

Add to Reading List

Source URL: www.fda.gov

Language: English